Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

A legfontosabb adatok

Ki végzi
BioNTech SE
Hol
Athens, Bridgeton, Charlottesville, Chesterfield, Chicago, Cincinnati, Columbus, East Greenwich, Elmhurst, Farmington Hills, Fort Lauderdale, Galveston, Greenacres City, Hialeah, Hollywood, Honolulu, Houston, Knoxville, Lake Forest, Lincoln, Little River, Miami, Miami Lakes, Monroe, Oak Brook, Oklahoma City, Omaha, Orange, Palmetto Bay, Pembroke Pines, Phoenix, Port Orange, Portsmouth, Raleigh, San Diego, Savannah, Silver Spring, St Louis, Stockbridge, Syracuse, Tomball, Tustin és Wichita (Egyesült Államok)Mind a 57 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
1019 fő vett részt
Kezdés
2022. okt. 28.
Befejezés
2023. dec. 28.
A vizsgálat típusa
Beavatkozással járó, 18 csoport
A vizsgált kezelések
  • bivalent BNT162b2 (original/Omi BA.4/BA.5)
  • qIRV (22/23)
  • QIV
  • bIRV
  • tIRV
A regiszteradat frissítve
2025. július 23.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 40 feltétel megnézéseKevesebb

Egyéb feltételek

  • SSA: Inclusion Criteria:
  • Male or female participants 18 years of age and older
  • Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study
  • Capable of giving signed informed consent as described in the protocol
  • For participants 18 through 64 years of age: participants who have received 3 prior doses of 30 µg BNT162b2, with the last dose being 150 to 365 days before Visit 1 (Day 1)
  • For participants 65 years of age and older: participants who have received 4 or 5 prior doses of a modRNA SARS-CoV-2 vaccine, with the last dose being a bivalent vaccine, 120 days to 365 days before Visit 1 (Day 1)
  • For Participants 65 years of age and older: receipt of licensed influenza vaccination for the 2022-2023 northern hemisphere season 120 days or more before study intervention administration; SSA: Exclusion Criteria:
  • History of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
  • Immunocompromised individuals with known or suspected immunodeficiency
  • Bleeding diathesis or condition associated with prolonged bleeding
  • Women who are pregnant or breastfeeding
  • Allergy to egg proteins (egg or egg products) or chicken proteins
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study
  • For participants 18 through 64 years of age: vaccination with any investigational or licensed influenza vaccine within 6 months (175 days) before study intervention administration
  • Participation in other studies involving a study intervention within 28 days before randomization. Anticipated participation in other studies within 28 days after receipt of study intervention in this study
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members
  • Participation in strenuous or endurance exercise through Visit 3 of the study
  • Prior history of heart disease
  • Any abnormal screening troponin I laboratory value
  • Screening 12-lead ECG that, as judged by the investigator, is consistent with probable or possible myocarditis or pericarditis, or demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results; SSB: Inclusion Criteria
  • Male or female participants 18 years of age and older
  • Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study
  • Capable of giving signed informed consent as described in the protocol
  • Participants who have received at least 3 prior US-authorized mRNA COVID-19 vaccines, with the last dose being an updated (bivalent) vaccine given at least 150 days before Day 1; SSB: Exclusion Criteria
  • Medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • History of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study
  • Vaccination with any investigational or licensed influenza vaccine within 6 months (175 days) before study intervention administration, or ongoing receipt of chronic antiviral therapy with activity against influenza
  • Participation in other studies involving administration of a study intervention within 28 days prior to, and/or during, participation in this study
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members
  • Initial enrollment only: Participation in strenuous or endurance exercise through Visit 3 (initial enrollment phase)
  • Initial enrollment only: Prior history of heart disease of concern
  • Initial enrollment only: Screening 12-lead ECG that, as judged by the investigator, is consistent with probable or possible myocarditis or pericarditis, or demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results

Helyszínek itt: Egyesült Államok

  • North Alabama Research CenterAthens, Egyesült Államok
  • The Heart CenterAthens, Egyesült Államok
  • Pradeep Chandra, DO, FACCBridgeton, Egyesült Államok
  • Charlottesville Medical ResearchCharlottesville, Egyesült Államok
  • Clinical Research ProfessionalsChesterfield, Egyesült Államok
  • Great Lakes Clinical Trials - RavenswoodChicago, Egyesült Államok
  • CTI Clinical Research CenterCincinnati, Egyesült Államok
  • Centricity Research Columbus Ohio MultispecialtyColumbus, Egyesült Államok
  • Velocity Clinical Research, ProvidenceEast Greenwich, Egyesült Államok
  • Retina AssociatesElmhurst, Egyesült Államok
  • Michigan Center of Medical Research (MICHMER)Farmington Hills, Egyesült Államok
  • Proactive Clinical Research,LLCFort Lauderdale, Egyesült Államok
  • University of Texas Medical BranchGalveston, Egyesült Államok
  • Finlay Medical ResearchGreenacres City, Egyesült Államok
  • Indago Research & Health Center, IncHialeah, Egyesült Államok
  • Research Centers of America (Hollywood)Hollywood, Egyesült Államok
  • East-West Medical Research InstituteHonolulu, Egyesült Államok
  • Prolato Clinical Research CenterHouston, Egyesült Államok
  • Alliance for Multispecialty Research, LLCKnoxville, Egyesült Államok
  • Orange County Research CenterLake Forest, Egyesült Államok
  • Pioneer Heart InstituteLincoln, Egyesült Államok
  • Main Street Physician's CareLittle River, Egyesült Államok
  • McLeod Cardiology Associates - Little RiverLittle River, Egyesült Államok
  • Angels Clinical Research InstituteMiami, Egyesült Államok
  • Entrust Clinical ResearchMiami, Egyesült Államok
  • Gerardo Polanco, MDMiami, Egyesült Államok
  • Jackson Medical Group Cardiac CareMiami, Egyesült Államok
  • Miami Clinical ResearchMiami, Egyesült Államok
  • Miami Dade Medical Research Institute, LLCMiami, Egyesült Államok
  • Research Institute of South FloridaMiami, Egyesült Államok
  • Palm Springs Community Health CenterMiami Lakes, Egyesült Államok
  • Panax Clinical ResearchMiami Lakes, Egyesült Államok
  • Monroe Biomedical ResearchMonroe, Egyesült Államok
  • Affinity HealthOak Brook, Egyesült Államok
  • Alliance for Multispecialty Research, LLCOak Brook, Egyesült Államok
  • Lynn Health Science InstituteOklahoma City, Egyesült Államok
  • Quality Clinical ResearchOmaha, Egyesült Államok
  • Velocity Clinical Research - OmahaOmaha, Egyesült Államok
  • Orange County Heart InstituteOrange, Egyesült Államok
  • Innovation Medical Research CenterPalmetto Bay, Egyesült Államok
  • DBC Research USAPembroke Pines, Egyesült Államok
  • Hope Research InstitutePhoenix, Egyesült Államok
  • The Pain Center of ArizonaPhoenix, Egyesült Államok
  • United Medical ResearchPort Orange, Egyesült Államok
  • ActivMed Practices & Research, LLC.Portsmouth, Egyesült Államok
  • M3 Wake Research, Inc.Raleigh, Egyesült Államok
  • California Research FoundationSan Diego, Egyesült Államok
  • Savannah Medical GroupSavannah, Egyesült Államok
  • Velocity Clinical Research - SavannahSavannah, Egyesült Államok
  • Jadestone Clinical ResearchSilver Spring, Egyesült Államok
  • Sundance Clinical ResearchSt Louis, Egyesült Államok
  • Clinical Research AtlantaStockbridge, Egyesült Államok
  • SUNY Upstate Medical University Institute for Global HealthSyracuse, Egyesült Államok
  • DM Clinical ResearchTomball, Egyesült Államok
  • DM Clinical Research - Martin Diagnostic ClinicTomball, Egyesült Államok
  • Orange County Research CenterTustin, Egyesült Államok
  • Alliance for Multispecialty Research LLCWichita, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Substudy A: This is a Phase 1 randomized, open-label study to describe the safety and immunogenicity of up to 3 dose- level combinations of modRNA quadrivalent influenza vaccine (qIRV (22/23)) and bivalent BNT162b2 (original/Omi BA.4/BA.5). Participants will receive either:

A teljes eredeti leírásKevesebb

* qIRV (22/23)/bivalent BNT162b2 (original/Omi BA.4/BA.5), at 1 of the 3 dose-level combinations * qIRV (22/23) at dose level 1, * qIRV (22/23) at dose level 2, or * bivalent BNT162b2 (original/Omi BA.4/BA.5) at dose level 1 administered concurrently in the opposite arm to commercially licensed quadrivalent influenza vaccine (QIV).

Substudy B: This Phase 1/2 study will describe the safety, tolerability, and immunogenicity of quadrivalent influenza vaccine (qIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), trivalent influenza vaccine (tIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), and bivalent influenza vaccine (bIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5) when given concurrently with licensed quadrivalent influenza vaccine (QIV).

A vizsgálat 18 csoportja

  • SSA: qIRV + bivalent BNT162b2 (dose level combination 1)A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSA: qIRV + bivalent BNT162b2 (dose level combination 2)A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSA: qIRV + bivalent BNT162b2 (dose level combination 3)A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSA: qIRV (dose level 1)A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: qIRV (22/23)

  • SSA: qIRV (dose level 2)A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: qIRV (22/23)

  • SSA: bivalent BNT162b2 (dose level 1) + QIVA vizsgált kezelés

    BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és QIV

  • SSB: QIV + bivalent BNT162b2 (original/Omi BA.4/BA.5)A vizsgált kezelés

    BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és QIV

  • SSB: QIV + bIRV/bivalent BNT162b2 (original/Omi BA.4/BA.5)A vizsgált kezelés

    BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5), QIV és bIRV

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 1A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 2A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 3A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 4A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 5A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 6A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 7A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 8A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és qIRV (22/23)

  • SSB: tIRV/bivalent BNT162b2(original/Omi\BA.4/BA.5)A vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: bivalent BNT162b2 (original/Omi BA.4/BA.5) és tIRV

  • SSB: qIRVA vizsgált kezelés

    Administered intramuscularly into the deltoid muscle of the right arm

    Kezelés: qIRV (22/23)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS
A regiszteradat frissítve
2025. július 23.